About Daniel Cameron, MD
Lyme Disease Research Clinical Trials
Dr. Daniel Cameron, an internist and epidemiologist, has been actively involved in clinical research as a principle investigator in the tick-borne illness field and as a sub-investigator for leading pharmaceutical companies. Several of his key research projects are listed below.
-
Genzyme
REACH Program
An International Prospective Observational Registry in Subjects at Risk of Atherothrombotic EventsWatson
MATRIX Trial
Multi-center Assessment of Transdermal Therapy in Overactive Bladder with Oxybutynin TDSMerck
Migraine Therapy Evaluation Protocol
Multi-center, Open-label, Crossover Study Comparing Maxalt with Usual Care
Oral Migraine MedicationDaniel Cameron, M.D., M.P.H.
Investigator – Pfizer Gemini Study
Combination Norvasc and Lipitor
Phase IIIb Open-label, multi-center trialDaniel Cameron, M.D., M.P.H.
Sub-investigator – Lyme Disease Retreatment Study
Mt. Sinai School of Medicine
-
Upjohn
Wound and soft tissue infection
Eli Lilly
Streptococcal pharyngitis
Uncomplicated urinary tract infection
Wound and soft tissue infectionG.D. Searle
Analgesic (phase I, II)
Squibb
Generalized anxiety
Eli Lilly
Acute bronchitis
Glaxo
Lyme Disease
Ciba-Geigy
Hypertension
Overview of LDPR
In addition to his writing and clinical work, Dr. Cameron conducts epidemiological research through the Lyme Disease Practice & Research (LDPR) center, located at his private practice in Mount Kisco, New York …more
Benefits of Lyme Research
Through LDPR, patients gain access to clinical trials by the same doctors who are treating them, and they are often among the first to receive new, proven therapies for their disease. more
Published Papers
Dr. Daniel Cameron has published more than 30 scientific papers, covering a range of topics in the tick-borne disease field. Many papers have been featured in lectures in the United States, Europe and Canada …more